Skip to main content

View full-text article in PMC

. 2023 Apr 8;149(10):8117–8129. doi: 10.1007/s00432-023-04735-w

Table 7.

Patient responses in the clinical trials that used RECIST V.1.1 criteria

	Lee et al. (2020)			Bazan-Peregrino et al. (2021)	Garcia-Carbonero et al. (2022)
	Lee et al. (2020)			Bazan-Peregrino et al. (2021)	Part 2	Part 3
Dose (viral particles)	10¹¹	3 × 10¹¹	10¹²	All	All	All
Total follow-up duration	6.5 months			31 + months	48 + months	29.6 + months
Timing of CT evaluations	12 weeks and 6.5 months			Every 8 weeks	Every 8 weeks
Complete response (%)	0.0	0.0	0.0	0.0	8.3	0.0
Partial response (%)	0.0	33.3	0.0	12.5	33.3	42.9
Stable disease (%)	100.0	33.3	66.6	75.0	41.7	42.9
Progressive disease (%)	0.0	33.3	33.3	0.0	0.0	0.0
Not evaluable (%)	0.0	0.0	0.0	12.5	16.7	14.3